The 3 most recent market catalysts affecting $DNA, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Sep 16, 2026
Corporate Catalyst
Bullish
Impact 75
Ginkgo Bioworks Announces Ginkgo Datapoints Agreement With Eli Lilly's TuneLab To Provide Small Molecule And Antibody Developability Testing
This headline represents a significant corporate catalyst for Ginkgo Bioworks (DNA), as securing a partnership with a pharmaceutical giant like Eli Lilly (LLY) validates its techno…
Sep 4, 2026
Corporate Catalyst
Neutral
Impact 55
BTIG Reiterates Sell on Ginkgo Bioworks Holdings, Maintains $5 Price Target
This 8-K filing discloses that BTIG analyst Mark Massaro has reiterated a 'Sell' rating on Ginkgo Bioworks Holdings (DNA) and maintained a $5 price target. This action signals a co…
Aug 7, 2026
Corporate Catalyst
Bearish
Impact 65
TD Cowen Downgrades Ginkgo Bioworks Holdings to Hold, Lowers Price Target to $9
TD Cowen analyst Brendan Smith downgraded Ginkgo Bioworks Holdings (DNA) from a 'Buy' rating to a 'Hold' rating and simultaneously lowered the price target from $12 to $9. This act…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.